{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:51:23Z","timestamp":1794354683563,"version":"4.9.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:p>Background: Characterizing patients with Parkinson\u2019s disease (PD) and cognitive impairment is important toward understanding their natural history. Objective: Understand clinical, treatment, and cost characteristics of patients with PD pre- and post-cognitive impairment (memory loss\/mild cognitive impairment\/dementia or dementia treatment) recognition. Methods: 2,711 patients with PD newly diagnosed with cognitive impairment (index) were identified using administrative claims data. They were matched (1:1) on age and gender to patients with PD and no cognitive impairment (controls). These two cohorts were compared on patient characteristics, healthcare resource utilization, and total median costs for 3 years pre- and post-index using Chi-square tests, t-tests, and Wilcoxon rank-sum tests. Logistic regression was used to identify factors predicting cognitive impairment. Results: Comorbidity indices for patients with cognitive impairment increased during the 6-year study period, especially after the index. Enrollment in Medicare Advantage Prescription Drug plans vs. commercial (OR\u200a=\u200a1.60), dual Medicare\/Medicaid eligibility (OR\u200a=\u200a1.36), cerebrovascular disease (OR\u200a=\u200a1.24), and PD medication use (OR\u200a=\u200a1.46) were associated with a new cognitive impairment diagnosis (all p\u200a&lt;\u200a0.05). A greater proportion of patients with cognitive impairment had hospitalizations and emergency department visits and higher median total healthcare costs than controls for each year pre- and post-index. Conclusion: In patients with PD newly diagnosed with cognitive impairment, comorbidity burden, hospitalizations, emergency department visits, and total costs peaked 1-year pre- and post-identification. These data coupled with recommendations for annual screening for cognitive impairment in PD support the early diagnosis and management of cognitive impairment in order to optimize care for patients and their caregivers.<\/jats:p>","DOI":"10.3233\/jpd-202190","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T11:01:02Z","timestamp":1615546862000},"page":"1381-1392","source":"Crossref","is-referenced-by-count":29,"title":["Characteristics of Parkinson\u2019s Disease in Patients with and without Cognitive Impairment"],"prefix":"10.1177","volume":"11","author":[{"given":"Julie M.","family":"Chandler","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Nair","sequence":"additional","affiliation":[{"name":"Humana Healthcare Research, Inc., Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Biglan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Ferries","sequence":"additional","affiliation":[{"name":"Humana Healthcare Research, Inc., Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne M.","family":"Munsie","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tich","family":"Changamire","sequence":"additional","affiliation":[{"name":"Humana Healthcare Research, Inc., Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Patel","sequence":"additional","affiliation":[{"name":"Humana Healthcare Research, Inc., Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-202190_ref1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202190_ref2","first-page":"1365","article-title":"Mild cognitive impairment in Parkinson\u2019s disease","volume":"64","author":"Wada","year":"2012","journal-title":"Brain Nerve"},{"key":"10.3233\/JPD-202190_ref3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-202190_ref4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3233\/JPD-171257","article-title":"Cognitive impairment and mortality in a population-based Parkinson\u2019s disease cohort","volume":"8","author":"Keener","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-202190_ref5","first-page":"869","article-title":"Diagnosis and treatment of cognitive impairment in Parkinson\u2019s disease","volume":"71","author":"Shiraishi","year":"2019","journal-title":"Brain Nerve"},{"key":"10.3233\/JPD-202190_ref6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00702-019-02003-1","article-title":"Mild cognitive impairment in Parkinson\u2019s disease","volume":"126","author":"Martinez-Horta","year":"2019","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JPD-202190_ref7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ane.13158","article-title":"Subjective cognitive complaints in patients with Parkinson\u2019s disease","volume":"140","author":"Kjeldsen","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.3233\/JPD-202190_ref8","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202190_ref9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ana.20635","article-title":"Neuropathology of dementia in Parkinson\u2019s disease: A prospective, community-based study","volume":"58","author":"Aarsland","year":"2005","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202190_ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0891988719853043","article-title":"Care burden and mental ill health in spouses of people with Parkinson disease dementia and lewy body dementia","volume":"33","author":"Vatter","year":"2020","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.3233\/JPD-202190_ref11","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2147\/NDT.S213917","article-title":"Impact of non-motor symptoms in Parkinson\u2019s disease: A PMD Alliance survey","volume":"15","author":"Hermanowicz","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.3233\/JPD-202190_ref12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z","article-title":"Mental symptoms in Parkinson\u2019s disease are important contributors to caregiver distress","volume":"14","author":"Aarsland","year":"1999","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JPD-202190_ref13","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1212\/WNL.0b013e3181ff96dd","article-title":"Quality improvement in neurology: AAN Parkinson disease quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology","volume":"75","author":"Cheng","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JPD-202190_ref14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/13803395.2015.1087465","article-title":"Mild cognitive impairment in Parkinson\u2019s disease: Diagnosis and progression to dementia","volume":"38","author":"Galtier","year":"2016","journal-title":"J Clin Exp Neuropsychol"},{"key":"10.3233\/JPD-202190_ref15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JPD-130304","article-title":"Parkinson\u2019s disease mild cognitive impairment: Application and validation of the criteria","volume":"4","author":"Geurtsen","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-202190_ref16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11910-011-0203-1","article-title":"Mild cognitive impairment in Parkinson\u2019s disease","volume":"11","author":"Aarsland","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.3233\/JPD-202190_ref17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: The inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202190_ref18","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/mds.23823","article-title":"MDS Task Force on mild cognitive impairment in Parkinson\u2019s disease: Critical review of PD-MCI","volume":"15","author":"Litvan","year":"2011","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202190_ref19","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","article-title":"Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis","volume":"75","author":"Aarsland","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JPD-202190_ref20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.27902","article-title":"Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: A meta-analysis","volume":"35","author":"Baiano","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202190_ref21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.3233\/JPD-202190_ref22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The incidence of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"4","author":"Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.3233\/JPD-202190_ref23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/mds.27277","article-title":"Parkinson disease with and without dementia: A prevalence study and future projections","volume":"33","author":"Savica","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-202190_ref24","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1002\/ana.21455","article-title":"Parkinson\u2019s disease dementia: Definitions, guidelines, and research perspectives in diagnosis","volume":"64","author":"Goetz","year":"2008","journal-title":"Ann Neurol"},{"key":"10.3233\/JPD-202190_ref28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.3233\/JPD-202190_ref29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.3233\/JPD-202190_ref30","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.3233\/JPD-202190_ref31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/01.MLR.0000064641.84967.B7","article-title":"Construction and characteristics of the RxRisk-V: A VA-adapted pharmacy-based case-mix instrument","volume":"41","author":"Sloan","year":"2003","journal-title":"Med Care"},{"key":"10.3233\/JPD-202190_ref32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1017\/S1355617717000017","article-title":"Are Parkinson\u2019s patients more vulnerable to the effects of cardiovascular risk: A neuroimaging and neuropsychological study","volume":"23","author":"Jones","year":"2017","journal-title":"J Int Neuropsychol Soc"},{"key":"10.3233\/JPD-202190_ref33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3233\/JAD-150610","article-title":"Vascular risk factors and cognition in Parkinson\u2019s disease","volume":"51","author":"Pilotto","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JPD-202190_ref34","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"key":"10.3233\/JPD-202190_ref35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/jcbfm.2015.164","article-title":"The neuropathology and cerebrovascular mechanisms of dementia","volume":"36","author":"Raz","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JPD-202190_ref36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1212\/WNL.0000000000001715","article-title":"Nursing home and end-of-life care in Parkinson disease","volume":"85","author":"Safarpour","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JPD-202190_ref37","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.parkreldis.2014.06.006","article-title":"Predictors of dementia in Parkinson\u2019s disease; findings from a 5-year prospective study using the SCOPA-COG","volume":"20","author":"Zhu","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-202190_ref38","first-page":"9","article-title":"Can levodopa prevent cognitive decline in patients with Parkinson\u2019s disease?","volume":"6","author":"Ikeda","year":"2017","journal-title":"Am J Neurodegener Dis"},{"key":"10.3233\/JPD-202190_ref39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/jnnp.2006.098079","article-title":"Effect of levodopa on cognitive function in Parkinson\u2019s disease with and without dementia and dementia with Lewy bodies","volume":"77","author":"Molloy","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-202190_ref40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/1533317513488911","article-title":"The clinical and economic burden of newly diagnosed Alzheimer\u2019s disease in a Medicare advantage population","volume":"28","author":"Suehs","year":"2013","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.3233\/JPD-202190_ref41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12877-018-0920-2","article-title":"Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer\u2019s disease in an administrative claims database","volume":"18","author":"Nair","year":"2018","journal-title":"BMC Geriatr"},{"key":"10.3233\/JPD-202190_ref42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/WAD.0000000000000277","article-title":"Increased health care utilization in dementia subtypes before diagnosis","volume":"32","author":"Albrecht","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JPD-202190_ref43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.dadm.2018.12.005","article-title":"Trends in health service use and potentially avoidable hospitalizations before Alzheimer\u2019s disease diagnosis: A matched, retrospective study of US Medicare beneficiaries","volume":"11","author":"Desai","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JPD-202190_ref44","first-page":"3","article-title":"Medical and non-medical costs of Parkinson disease - comparison of Europe, USA, Asia and Australia","volume":"66","author":"Mare\u0161ov\u00e1","year":"2017","journal-title":"Ceska Slov Farm"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-202190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:48:49Z","timestamp":1777610929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-202190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":41,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jpd-202190","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}